# Microbial Products (Synthetic Biology) Sector

Canonical URL: https://biopharmsignal.com/sector/microbial-products-synthetic-biology

Microbial Products (Synthetic Biology) groups companies using engineered microbes, microbial systems, or synthetic biology workflows to produce therapeutic or industrial biological products. It is a cross-disciplinary category that blends platform biology with scalable manufacturing logic.

Companies currently grouped under Microbial Products (Synthetic Biology): 16

## Recent Sector News

- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9) — Source: Enlivex Therapeutics
- 2026-07-14 11:02 EST — SPRO — [Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-financing-bac-d8d87fa7) — Source: Spero Therapeutics
- 2026-06-30 13:00 EST — SNOA — [Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution](https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-receives-fda-510-k-clearance-expanding-indications-and-pa-421ff719) — Source: Sonoma Pharmaceuticals
- 2026-06-16 20:15 EST — SNOA — [Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results](https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2026-financial-res-04e8ed16) — Source: Sonoma Pharmaceuticals
- 2026-06-04 11:00 EST — ANTX — [AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-positive-enabling-data-supporting-advancement-of-oral-an2-502998-to-phase-2-study-for-chronic-chagas-disease) — Source: AN2 Therapeutics
- 2026-06-02 08:00 EST — ENLV — [ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026](https://biopharmsignal.com/news/ENLV/enlivex-to-present-quality-longevity-model-powered-by-prediction-markets-treasury-at-proof-of-talk-2026) — Source: Enlivex Therapeutics
- 2026-06-01 08:00 EST — ENLV — [Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026](https://biopharmsignal.com/news/ENLV/allocetra-shows-durable-6-month-efficacy-in-knee-osteoarthritis-phase-iia-trial-oral-presentation-at-eular-2026) — Source: Enlivex Therapeutics
- 2026-05-28 08:00 EST — ENLV — [Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-holdings-valued-at-approximately-1-16-billion-rain-foundation-appoints-industry-leaders-to-advisory-board) — Source: Enlivex Therapeutics
- 2026-05-27 12:00 EST — TWST — [Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/TWST/twist-bioscience-to-present-at-william-blair-46th-annual-growth-stock-conference) — Source: Twist Bioscience Corporation
- 2026-05-27 08:00 EST — ENLV — [Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-protocol-jumps-into-top-three-global-prediction-markets-in-league-table-following-100m-in-additional-liquidity) — Source: Enlivex Therapeutics
- 2026-05-21 11:00 EST — ANTX — [AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-present-at-2026-jefferies-global-healthcare-conference) — Source: AN2 Therapeutics
- 2026-05-19 01:55 EST — RPID — [Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-announces-pricing-of-up-to-approximately-32-million-underwritten-offering) — Source: Rapid Micro Biosystems
- 2026-05-18 08:00 EST — ENLV — [Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis](https://biopharmsignal.com/news/ENLV/enlivex-announces-dosing-of-first-patient-in-the-united-states-as-part-of-its-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis) — Source: Enlivex Therapeutics
- 2026-05-15 16:10 EST — ENLV — [Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification](https://biopharmsignal.com/news/ENLV/enlivex-announces-receipt-of-nasdaq-minimum-bid-price-notification) — Source: Enlivex Therapeutics
- 2026-05-14 12:00 EST — LUCD — [Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: Lucid Diagnostics
- 2026-05-13 20:26 EST — RPID — [Rapid Micro Biosystems Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-reports-first-quarter-2026-financial-results) — Source: Rapid Micro Biosystems
- 2026-05-13 16:05 EST — SPRO — [Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2026-operating-results-and-provides-business-update) — Source: Spero Therapeutics
- 2026-05-11 20:01 EST — ANTX — [AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-and-scientific-highlights) — Source: AN2 Therapeutics
- 2026-05-07 20:06 EST — ABSI — [Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/ABSI/absci-reports-business-updates-and-first-quarter-2026-financial-and-operating-results) — Source: Absci Corporation
- 2026-05-07 20:01 EST — ANTX — [AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum) — Source: AN2 Therapeutics

## Companies

- [ABSI](https://biopharmsignal.com/company/ABSI) — Absci Corporation
- [AXDX](https://biopharmsignal.com/company/AXDX) — Accelerate Diagnostics
- [ACXP](https://biopharmsignal.com/company/ACXP) — Acurx Pharmaceuticals
- [ANTX](https://biopharmsignal.com/company/ANTX) — AN2 Therapeutics
- [ARMP](https://biopharmsignal.com/company/ARMP) — Armata Pharmaceuticals
- [CARM](https://biopharmsignal.com/company/CARM) — Carisma Therapeutics, Inc.
- [ENLV](https://biopharmsignal.com/company/ENLV) — Enlivex Therapeutics
- [DNA](https://biopharmsignal.com/company/DNA) — Ginkgo Bioworks Holdings, Inc.
- [ITRM](https://biopharmsignal.com/company/ITRM) — Iterum Therapeutics
- [LUCD](https://biopharmsignal.com/company/LUCD) — Lucid Diagnostics
- [RPID](https://biopharmsignal.com/company/RPID) — Rapid Micro Biosystems
- [SNTI](https://biopharmsignal.com/company/SNTI) — Senti Biosciences
- [SNOA](https://biopharmsignal.com/company/SNOA) — Sonoma Pharmaceuticals
- [SPRO](https://biopharmsignal.com/company/SPRO) — Spero Therapeutics
- [SYBX](https://biopharmsignal.com/company/SYBX) — Synlogic
- [TWST](https://biopharmsignal.com/company/TWST) — Twist Bioscience Corporation